Clinical trial
Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating…
NCT00088855 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00088855 |
|---|---|
| Title | Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma |
| Official title | Phase II Study of Bortezomib (PS-341) and Pegylated Liposomal Doxorubicin as Initial Therapy for Adult Patients With Symptomatic Multiple Myeloma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma |
| Intervention type | Drug, Other |
| Interventions | Bortezomib, Laboratory Biomarker Analysis, Pegylated Liposomal Doxorubicin Hydrochloride |
| Enrollment | 55 |
| Start date | Jun 15, 2004 |
| Primary completion | Oct 31, 2006 |
| Completion | Jan 8, 2008 |
| First posted | Aug 5, 2004 |
| Last update posted | Sep 23, 2019 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: